当前位置: 首页 >> 检索结果
61. Treatment of tobacco use in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: Frank T Leone.;Sarah Evers-Casey.;Benjamin A Toll.;Anil Vachani.
来源: Chest. 2013年143卷5 Suppl期e61S-e77S页
Continued tobacco use in the setting of lung cancer management is frequently confounding and always of critical importance. We summarized the published literature concerning the management of tobacco dependence in patients with lung cancer and offer recommendations for integrating dependence treatment into ongoing oncologic care.
62. Palliative and end-of-life care in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: Dee Walker Ford.;Kathryn A Koch.;Daniel E Ray.;Paul A Selecky.
来源: Chest. 2013年143卷5 Suppl期e498S-e512S页
In the United States, lung cancer is a major health problem that is associated with significant patient distress and often limited survival, with some exceptions. The purpose of this article is to address the role of palliative and end-of-life care in the management of patients with lung cancer and to address the need for good communication skills to provide support to patients and families.
63. Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: Michael J Simoff.;Brian Lally.;Mark G Slade.;Wendy G Goldberg.;Pyng Lee.;Gaetane C Michaud.;Momen M Wahidi.;Mohit Chawla.
来源: Chest. 2013年143卷5 Suppl期e455S-e497S页
Many patients with lung cancer will develop symptoms related to their disease process or the treatment they are receiving. These symptoms can be as debilitating as the disease progression itself. To many physicians these problems can be the most difficult to manage.
64. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: Henri G Colt.;Septimiu D Murgu.;Robert J Korst.;Christopher G Slatore.;Michael Unger.;Silvia Quadrelli.
来源: Chest. 2013年143卷5 Suppl期e437S-e454S页
These guidelines are an update of the evidence-based recommendations for follow-up and surveillance of patients after curative-intent therapy for lung cancer. Particular updates pertain to whether imaging studies, health-related quality-of-life (HRQOL) measures, tumor markers, and bronchoscopy improve outcomes after curative-intent therapy.
65. Complementary therapies and integrative medicine in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: Gary E Deng.;Sarah M Rausch.;Lee W Jones.;Amitabh Gulati.;Nagi B Kumar.;Heather Greenlee.;M Catherine Pietanza.;Barrie R Cassileth.
来源: Chest. 2013年143卷5 Suppl期e420S-e436S页
Physicians are often asked about complementary therapies by patients with cancer, and data show that the interest in and use of these therapies among patients with cancer is common. Therefore, it is important to assess the current evidence base on the benefits and risks of complementary therapies (modalities not historically used in modern Western medicine).
66. Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: Eva Szabo.;Jenny T Mao.;Stephen Lam.;Mary E Reid.;Robert L Keith.
来源: Chest. 2013年143卷5 Suppl期e40S-e60S页
Lung cancer is the most common cause of cancer death in men and women in the United States. Cigarette smoking is the main risk factor. Former smokers are at a substantially increased risk of developing lung cancer compared with lifetime never smokers. Chemoprevention refers to the use of specific agents to reverse, suppress, or prevent the process of carcinogenesis. This article reviews the major agents that have been studied for chemoprevention.
67. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: James R Jett.;Steven E Schild.;Kenneth A Kesler.;Gregory P Kalemkerian.
来源: Chest. 2013年143卷5 Suppl期e400S-e419S页
Small cell lung cancer (SCLC) is a lethal disease for which there have been only small advances in diagnosis and treatment in the past decade. Our goal was to revise the evidence-based guidelines on staging and best available treatment options.
68. Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: Benjamin D Kozower.;James M Larner.;Frank C Detterbeck.;David R Jones.
来源: Chest. 2013年143卷5 Suppl期e369S-e399S页
This guideline updates the second edition and addresses patients with particular forms of non-small cell lung cancer that require special considerations, including Pancoast tumors, T4 N0,1 M0 tumors, additional nodules in the same lobe (T3), ipsilateral different lobe (T4) or contralateral lung (M1a), synchronous and metachronous second primary lung cancers, solitary brain and adrenal metastases, and chest wall involvement.
69. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: Mark A Socinski.;Tracey Evans.;Scott Gettinger.;Thomas A Hensing.;Lecia VanDam Sequist.;Belinda Ireland.;Thomas E Stinchcombe.
来源: Chest. 2013年143卷5 Suppl期e341S-e368S页
Stage IV non-small cell lung cancer (NSCLC) is a treatable, but not curable, clinical entity in patients given the diagnosis at a time when their performance status (PS) remains good.
70. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: Nithya Ramnath.;Thomas J Dilling.;Loren J Harris.;Anthony W Kim.;Gaetane C Michaud.;Alex A Balekian.;Rebecca Diekemper.;Frank C Detterbeck.;Douglas A Arenberg.
来源: Chest. 2013年143卷5 Suppl期e314S-e340S页
Stage III non-small cell lung cancer (NSCLC) describes a heterogeneous population with disease presentation ranging from apparently resectable tumors with occult microscopic nodal metastases to unresectable, bulky nodal disease. This review updates the published clinical trials since the last American College of Chest Physicians guidelines to make treatment recommendations for this controversial subset of patients.
71. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: John A Howington.;Matthew G Blum.;Andrew C Chang.;Alex A Balekian.;Sudish C Murthy.
来源: Chest. 2013年143卷5 Suppl期e278S-e313S页
The treatment of stage I and II non-small cell lung cancer (NSCLC) in patients with good or low surgical risk is primarily surgical resection. However, this area is undergoing many changes. With a greater prevalence of CT imaging, many lung cancers are being found that are small or constitute primarily ground-glass opacities. Treatment such as sublobar resection and nonsurgical approaches such as stereotactic body radiotherapy (SBRT) are being explored. With the advent of minimally invasive resections, the criteria to classify a patient as too ill to undergo an anatomic lung resection are being redefined.
72. Diagnosis and treatment of bronchial intraepithelial neoplasia and early lung cancer of the central airways: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: Juan P Wisnivesky.;Rex Chin-Wei Yung.;Praveen N Mathur.;Javier J Zulueta.
来源: Chest. 2013年143卷5 Suppl期e263S-e277S页
Bronchial intraepithelial lesions may be precursors of central airway lung carcinomas. Identification and early treatment of these preinvasive lesions might prevent progression to invasive carcinoma.
73. Diagnostic surgical pathology in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
This article provides evidence-based background and recommendations for the development of American College of Chest Physicians guidelines for the diagnosis and management of lung cancer. Specific population, intervention, comparison, and outcome questions were addressed to arrive at consensus recommendations.
74. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: Gerard A Silvestri.;Anne V Gonzalez.;Michael A Jantz.;Mitchell L Margolis.;Michael K Gould.;Lynn T Tanoue.;Loren J Harris.;Frank C Detterbeck.
来源: Chest. 2013年143卷5 Suppl期e211S-e250S页
Correctly staging lung cancer is important because the treatment options and prognosis differ significantly by stage. Several noninvasive imaging studies and invasive tests are available. Understanding the accuracy, advantages, and disadvantages of the available methods for staging non-small cell lung cancer is critical to decision-making.
75. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: Alessandro Brunelli.;Anthony W Kim.;Kenneth I Berger.;Doreen J Addrizzo-Harris.
来源: Chest. 2013年143卷5 Suppl期e166S-e190S页
This section of the guidelines is intended to provide an evidence-based approach to the preoperative physiologic assessment of a patient being considered for surgical resection of lung cancer.
76. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Lung cancer is usually suspected in individuals who have an abnormal chest radiograph or have symptoms caused by either local or systemic effects of the tumor. The method of diagnosis of lung cancer depends on the type of lung cancer (small cell lung cancer or non-small cell lung cancer [NSCLC]), the size and location of the primary tumor, the presence of metastasis, and the overall clinical status of the patient. The objective of this study was to determine the test performance characteristics of various modalities for the diagnosis of suspected lung cancer.
77. Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: David E Ost.;Sai-Ching Jim Yeung.;Lynn T Tanoue.;Michael K Gould.
来源: Chest. 2013年143卷5 Suppl期e121S-e141S页
This guideline is intended to provide an evidence-based approach to the initial evaluation of patients with known or suspected lung cancer. It also includes an assessment of the impact of timeliness of care and multidisciplinary teams on outcome.
78. Executive Summary: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: Frank C Detterbeck.;Sandra Zelman Lewis.;Rebecca Diekemper.;Doreen Addrizzo-Harris.;W Michael Alberts.
来源: Chest. 2013年143卷5 Suppl期7S-37S页 79. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: Robert P Baughman.;Keith C Meyer.;Ian Nathanson.;Luis Angel.;Sangeeta M Bhorade.;Kevin M Chan.;Daniel Culver.;Christopher G Harrod.;Mary S Hayney.;Kristen B Highland.;Andrew H Limper.;Herbert Patrick.;Charlie Strange.;Timothy Whelan.
来源: Chest. 2012年142卷5期e1S-e111S页
Immunosuppressive pharmacologic agents prescribed to patients with diffuse interstitial and inflammatory lung disease and lung transplant recipients are associated with potential risks for adverse reactions. Strategies for minimizing such risks include administering these drugs according to established, safe protocols; monitoring to detect manifestations of toxicity; and patient education. Hence, an evidence-based guideline for physicians can improve safety and optimize the likelihood of a successful outcome. To maximize the likelihood that these agents will be used safely, the American College of Chest Physicians established a committee to examine the clinical evidence for the administration and monitoring of immunosuppressive drugs (with the exception of corticosteroids) to identify associated toxicities associated with each drug and appropriate protocols for monitoring these agents.
80. Executive summary: monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.
作者: Robert P Baughman.;Keith C Meyer.;Ian Nathanson.;Luis Angel.;Sangeeta M Bhorade.;Kevin M Chan.;Daniel Culver.;Christopher G Harrod.;Mary S Hayney.;Kristen B Highland.;Andrew H Limper.;Herbert Patrick.;Charlie Strange.;Timothy Whelan.
来源: Chest. 2012年142卷5期1284-1288页 |